Methods of monitoring mutations in treatment of colorectal cancer
AssigneeCardiff Oncology, Inc.
InventorsMaya Ridinger, Errin Samuelsz, Tod Smeal
Life of this patent
Estimating the term…
Abstract
Provided includes methods, compositions and kits for improving outcome of a treatment for colorectal cancer, and methods, compositions and kits for determining responsiveness of a subject to a treatment for colorectal cancer. Determining responsiveness can comprise determining change(s) in mean level of somatic mutations of at least three genes in the subject. The treatment for colorectal cancer can comprise administering PLK1 inhibitor (e.g., onvansertib) and bevacizumab to the subject.
Claims79
A method of predicting or determining responsiveness of a subject to a treatment for colorectal cancer, comprising:
- treating the subject with colorectal cancer, wherein the treatment for colorectal cancer comprises administering a PLK1 inhibitor and bevacizumab to the subject;
- detecting change(s) in mean level of somatic mutations of at least three genes in the subject, wherein the at least three genes comprise KRAS, APC and TP53 genes;
- and
- determining the responsiveness of the subject to the treatment for colorectal cancer based on the detected change(s) in mean level of somatic mutations.
A method of improving outcome of a treatment for colorectal cancer, comprising:
- detecting mean variant allele frequency of a first set of at least three genes in a subject at a first time point in a first sample, wherein the first set of the at least three genes comprise KRAS, APC and TP53 genes, wherein the first time point is before the subject starts the treatment for colorectal cancer, or during the treatment for colorectal cancer, and wherein the treatment for colorectal cancer comprises administering a PLK1 inhibitor and bevacizumab to the subject;
- detecting mean variant allele frequency of a second set of at least three gene in the subject at one or more additional time points in one or more additional samples, wherein the second set of the at least three genes comprise KRAS, APC and TP53 genes, and wherein the at least one of the one or more additional time points is during the treatment for colorectal cancer;
- determining the difference of the mean variant allele frequency between the first and the one or more additional samples, wherein a decrease in the mean variant allele frequency in at least one of the one or more additional samples relative to the first sample indicates the subject as responsive to the treatment for colorectal cancer;
- and
- continuing the treatment for colorectal cancer to the subject if the subject is indicated as responsive to the treatment for colorectal cancer, or discontinuing the treatment for colorectal cancer to the subject and/or starting a different treatment to the subject if the subject is not indicated as responsive to the treatment for colorectal cancer.
A method of treating colorectal cancer, comprising:
- treating a subject with colorectal cancer, wherein the treating comprises administering a PLK1 inhibitor and bevacizumab to the subject;
- determining a decrease, relative to a mean variant allele frequency of a first set of at least three genes in a first sample of the subject obtained at a first time point before the subject receives the treatment for colorectal cancer or during the treatment for colorectal cancer, in a mean variant allele frequency of a second set of at least three gene in a second sample of the subject obtained at a second time point after the subject starts receiving the treatment for colorectal cancer;
- and
- continuing with the treatment for colorectal cancer,
- wherein the first set of at least three genes and the second set of at least three genes comprise KRAS, APC and TP53 genes.
Dependencies are inferred from the claim text.